Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Chemours (NYSE:CC) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 1 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 2 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $29.25, with a high estimate of $34.00 and a low estimate of $25.00. Observing a 21.88% increase, the current average has risen from the previous average price target of $24.00.
Diving into Analyst Ratings: An In-Depth Exploration
The perception of Chemours by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| John Roberts | Mizuho | Announces | Neutral | $25.00 | - |
| John McNulty | BMO Capital | Raises | Outperform | $34.00 | $19.00 |
| Joshua Spector | UBS | Raises | Neutral | $28.00 | $21.00 |
| Michael Leithead | Barclays | Lowers | Equal-Weight | $30.00 | $32.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Chemours. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Chemours compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Chemours's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Chemours's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Chemours analyst ratings.
Discovering Chemours: A Closer Look
The Chemours Co is a global provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Chemours's Economic Impact: An Analysis
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Chemours's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -12.11%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Chemours's net margin is impressive, surpassing industry averages. With a net margin of 3.85%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Chemours's ROE stands out, surpassing industry averages. With an impressive ROE of 6.98%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Chemours's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.64% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 5.66, Chemours faces challenges in effectively managing its debt levels, indicating potential financial strain.
Analyst Ratings: Simplified
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.